Prospective clinical study of R-CMD therapy for indolent B-cell lymphoma and mantle cell lymphoma
Phase 2
- Conditions
- indolent B-cell lymphoma, mantle cell lymphoma
- Registration Number
- JPRN-UMIN000001341
- Lead Sponsor
- Hematology and Immunology, Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1, low or negative expression CD20 2, severe infectious disease 3, Pre-treatment history for lymphoma 4, HIV+, HTLV1+, HBs-Ag+, HBc-Ab high titer 5, Pt who will be treat by allogenic or autologous stem cell transplantation 6, physician's decision of inappropriateness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CR rate
- Secondary Outcome Measures
Name Time Method Adverse events, Overall survival, Overall response rate